Stock Ratings / Health Care / AGIO / options

PRGO (41) SDGR (43) VERA (35) HRMY (80) ⌘ Pro Terminal →

Agios Pharmaceuticals Inc. (AGIO) Options Positioning, Max Pain & Unusual Sweeps

$37.23 -2.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Agios Pharmaceuticals Inc. (AGIO) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.22B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGIO)Realized 20D OHLCV Swing Band: ±10.2%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±10.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AGIO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AGIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGIO)

✓Walkthrough of AGIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AGIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.96%▲ RESISTANCE BREAKOUT

2026-10-30O $31.43H $37.23L $29.80C $37.23VOL 3.09M

RES: $30.83SUP: $29.79SMA50: $33.62SMA200: $31.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AGIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AGIO Butterfly Map → + Track AGIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +48.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AGIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AGIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AGIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGIO)

Health Care Rank #660 of 1016 ⚔️ PRGO vs AGIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AGIO vs. PRGO, SDGR, VERA, HRMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Agios Pharmaceuticals Inc. (AGIO) ranks #660 by composite RQD confidence (39/100, grade D-) and #241 by equity capitalization ($2.22B). Within this direct 5-issuer industry benchmark cohort, HRMY leads on earnings valuation at 14.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with AGIO at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AGIO ACTIVE Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	Benchmark Subject
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-agio →
SDGR Schrodinger Inc.	D-	43/100	—	55.7%	-35.0%	-2.85%	$2.24B	/sdgr-vs-agio →
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-agio →
HRMY Harmony Biosciences Holdings Inc.	B+	80/100	14.2x	77.2%	63.0%	+0.23%	$2.25B	/hrmy-vs-agio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001439222

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Agios Pharmaceuticals Inc. (AGIO) reported GAAP revenue of $54.0M (+48.0% vs. FY2024 revenue of $36.5M , and +101.4% cumulative change since FY2023) , GAAP net income of -$413.0M, operating cash flow of -$373.0M, and free cash flow of -$377.3M (+3.6% YoY). On the balance sheet, AGIO closed FY2025 with $1.30B in total assets against $0 in total debt (Altman Z-Score: 11.84, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$54.0M	-$413.0M	-$373.0M	-$377.3M	$1.30B	—
FY2024 (FY)	2024-12-31	$36.5M	$674.0M	-$389.8M	-$391.5M	$1.66B	—
FY2023 (FY)	2023-12-31	$26.8M	-$352.0M	-$296.1M	-$296.1M	—	—

3. AGIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AGIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $37.23 (-2.33% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGIO ranks #660 in composite RQD confidence.

How does AGIO compare to PRGO and SDGR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AGIO carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 88.3%, and ROIC of -33.8%. By comparison, PRGO (Perrigo Company plc) holds a D- grade (41/100 RQD, P/E N/A, ROIC -13.6%, cap $2.21B) and SDGR (Schrodinger Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.24B). Among the 5-stock peer group, HRMY leads on earnings multiple (14.2x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AGIO?

Per AGIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439222), Agios Pharmaceuticals Inc. generated $54.0M in revenue (+48.0% YoY), -$413.0M in net income, and -$377.3M in free cash flow against $1.30B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AGIO trading relative to its 50-day, 200-day, and 52-week technical levels?

AGIO last traded at $37.23 (-2.33% on volume of 984,452 shares), positioning the stock +10.74% above its 50-day simple moving average ($33.62) and +17.44% above its 200-day simple moving average ($31.70). Across its 52-week range of $22.24 to $46.00, AGIO sits at the 63.1% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($33.43 to $41.03).

AGIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AGIO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AGIO.

Direct Sub-Reports: AGIO RQD Cockpit AGIO 12M Forecast AGIO Earnings & Move AGIO Dividends & DRIP AGIO Insiders & 13F AGIO Whale Options AGIO Profit Sankey AGIO News & Why